Natasha D Buchanan1, Sabitha Dasari2, Juan L Rodriguez3, Judith Lee Smith3, M Elizabeth Hodgson4, Clarice R Weinberg5, Dale P Sandler6. 1. Division of Cancer Prevention and Control, Epidemiology and Applied Research Branch, CDC, Atlanta, Georgia. Electronic address: nbuchanan@cdc.gov. 2. Northrop Grumman Corporation, Information Systems, Atlanta, Georgia. 3. Division of Cancer Prevention and Control, Epidemiology and Applied Research Branch, CDC, Atlanta, Georgia. 4. Social and Scientific Systems, Inc., Durham, North Carolina. 5. Biostatistics Branch, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina. 6. Epidemiology Branch, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina.
Abstract
INTRODUCTION: Chemotherapy for breast cancer has been associated with cognitive problems; however, the impact of adjuvant hormone therapy is less clear. No studies have explored provider discussions about cognitive concerns or factors associated with neurocognitive treatment. This study examined cognitive problems, factors associated with having a provider discussion, and receipt of neurocognitive treatment. METHODS: Female breast cancer survivors (N=2,537) from the Sister Study and the Two Sister Study who were at least 1 year post-treatment were surveyed in 2012 about their cancer therapies (confirmed by medical records); cognitive concerns; related provider discussions; and neurocognitive treatment. A total of 2,296 women were included in the current 2014 analysis. Extensive covariate information was also ascertained for predictive multivariate models. RESULTS: The prevalence of self-reported cognitive problems after treatment was 60%. Of those reporting cognitive problems, only 37% had discussed those concerns with a provider and 15% had been treated for cognitive symptoms. The odds of reported cognitive concerns that started during and after treatment were elevated for those who received only hormone therapy and no chemotherapy (OR=1.64, 95% CI=1.15, 2.33); chemotherapy and no hormone therapy (OR=5.63, 95% CI=3.52, 9.00); or both (OR=6.33, 95% CI=4.21, 9.54) compared with those reporting neither treatment. CONCLUSIONS: The high prevalence of cognitive concerns underscores the importance of monitoring breast cancer survivors for potential neurocognitive effects of hormone and chemotherapy, discussions with survivors about those concerns, and treatment referrals. Monitoring changes over time can help to evaluate both psychosocial and neurocognitive care provided for survivors. Published by Elsevier Inc.
INTRODUCTION: Chemotherapy for breast cancer has been associated with cognitive problems; however, the impact of adjuvant hormone therapy is less clear. No studies have explored provider discussions about cognitive concerns or factors associated with neurocognitive treatment. This study examined cognitive problems, factors associated with having a provider discussion, and receipt of neurocognitive treatment. METHODS: Female breast cancer survivors (N=2,537) from the Sister Study and the Two Sister Study who were at least 1 year post-treatment were surveyed in 2012 about their cancer therapies (confirmed by medical records); cognitive concerns; related provider discussions; and neurocognitive treatment. A total of 2,296 women were included in the current 2014 analysis. Extensive covariate information was also ascertained for predictive multivariate models. RESULTS: The prevalence of self-reported cognitive problems after treatment was 60%. Of those reporting cognitive problems, only 37% had discussed those concerns with a provider and 15% had been treated for cognitive symptoms. The odds of reported cognitive concerns that started during and after treatment were elevated for those who received only hormone therapy and no chemotherapy (OR=1.64, 95% CI=1.15, 2.33); chemotherapy and no hormone therapy (OR=5.63, 95% CI=3.52, 9.00); or both (OR=6.33, 95% CI=4.21, 9.54) compared with those reporting neither treatment. CONCLUSIONS: The high prevalence of cognitive concerns underscores the importance of monitoring breast cancer survivors for potential neurocognitive effects of hormone and chemotherapy, discussions with survivors about those concerns, and treatment referrals. Monitoring changes over time can help to evaluate both psychosocial and neurocognitive care provided for survivors. Published by Elsevier Inc.
Authors: Steven A Castellon; Patricia A Ganz; Julienne E Bower; Laura Petersen; Laura Abraham; Gail A Greendale Journal: J Clin Exp Neuropsychol Date: 2004-10 Impact factor: 2.475
Authors: K Robin Yabroff; Emily Dowling; Juan Rodriguez; Donatus U Ekwueme; Helen Meissner; Anita Soni; Catherine Lerro; Gordon Willis; Laura P Forsythe; Laurel Borowski; Katherine S Virgo Journal: J Cancer Surviv Date: 2012-07-19 Impact factor: 4.442
Authors: Laura P Forsythe; Erin E Kent; Kathryn E Weaver; Natasha Buchanan; Nikki A Hawkins; Juan L Rodriguez; A Blythe Ryerson; Julia H Rowland Journal: J Clin Oncol Date: 2013-04-22 Impact factor: 44.544
Authors: Heather S L Jim; Kristin M Phillips; Sari Chait; Leigh Anne Faul; Mihaela A Popa; Yun-Hsiang Lee; Mallory G Hussin; Paul B Jacobsen; Brent J Small Journal: J Clin Oncol Date: 2012-08-27 Impact factor: 44.544
Authors: Greta M Massetti; Kristin M Holland; Shane P D Jack; Kathleen R Ragan; Natasha Buchanan Lunsford Journal: Psychooncology Date: 2018-04-23 Impact factor: 3.894
Authors: Debra E Lyon; Ronald Cohen; Huaihou Chen; Debra L Kelly; Angela Starkweather; Hyo-Chol Ahn; Colleen K Jackson-Cook Journal: J Cancer Res Clin Oncol Date: 2016-04-21 Impact factor: 4.553
Authors: Sun Hee Rim; K Robin Yabroff; Sabitha Dasari; Xuesong Han; Kristin Litzelman; Donatus U Ekwueme Journal: Prev Med Date: 2019-03-16 Impact factor: 4.018
Authors: Erik Boberg; Nadir Kadri; Jeanette Winterling; Lindsay C Davies; Andreas Björklund; Mussie Msghina; Ellen Iacobaeus; Katarina Le Blanc Journal: Haematologica Date: 2019-10-24 Impact factor: 9.941
Authors: Chelsea Anderson; Dale P Sandler; Clarice R Weinberg; Kevin Houck; Minal Chunduri; M Elizabeth Hodgson; Susan A Sabatino; Mary C White; Juan L Rodriguez; Hazel B Nichols Journal: Breast Date: 2017-02-27 Impact factor: 4.380
Authors: Gee Su Yang; Sreelakshmy Kumar; Susan G Dorsey; Angela R Starkweather; Debra Lynch Kelly; Debra E Lyon Journal: Support Care Cancer Date: 2018-10-20 Impact factor: 3.603